Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Interim Budget 2024: EV ecosystem will get a boost, say auto sector analysts
- PhysicsWallah Shares Tumble 8%; Rs 8,400 Cr Market Cap Wiped Out In Just 3 Sessions Post Listing
- Stock Market Highlights: Sensex Sheds 800 Points, Nifty Down 200 As Oil Soars
- Funding Winter Bites Late Stage Consumer Internet Startups; Avg Ticket Size Sees 60% Drop
